• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

    9/2/22 4:58:20 PM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ICPT alert in real time by email
    SC 13G/A 1 brhc10041576_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     (Amendment No. 8)*


     
    INTERCEPT PHARMACEUTICALS, INC.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    45845P108
    (CUSIP Number)
     
    September 2, 2022
    (Date of Event Which Requires Filing of this Statement)
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     
    ☐
    Rule 13d-1(b)
     
     
    ☐
    Rule 13d-1(c)
     
     
    ☒
    Rule 13d-1(d)
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    NAMES OF REPORTING PERSONS
     
     
    Genextra S.p.A.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Italy
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    4,000,000 shares of Common Stock
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    4,000,000 shares of Common Stock
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,000,000 shares of Common Stock
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    13.4%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
      OO
     
     
     
     


    1
    NAMES OF REPORTING PERSONS
     
     
    Francesco Micheli
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a) ☐
       
    (b) ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Italy
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
      0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    4,000,000 shares of Common Stock
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    4,000,000 shares of Common Stock
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,000,000 shares of Common Stock
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    13.4%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     


    1
    NAMES OF REPORTING PERSONS
     
     
    Paolo Fundarò
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Italy
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    55,673 shares of Common Stock
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0 shares of Common Stock
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    55,673 shares of Common Stock
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     0 shares of Common Stock
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    55,673 shares of Common Stock
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.2%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    This Amendment No. 8 (this “Amendment”) amends and supplements the statement on Schedule 13G (the “Schedule 13G”), dated February 14, 2013, as subsequently amended by Amendment No. 1, dated February 13, 2014 (“Amendment No. 1”), Amendment No. 2, dated February 17, 2015 (“Amendment No. 2”), Amendment No. 3, dated April 9, 2018 (“Amendment No. 3”), Amendment No. 4, dated February 8, 2019 (“Amendment No. 4”), Amendment No. 5, dated July 25, 2019 (“Amendment No. 5”), Amendment No. 6, dated May 15, 2020 (“Amendment No. 6”), and Amendment No. 7, dated August 17, 2020 (“Amendment No. 7”) filed jointly by Genextra S.p.A. (“Genextra”), Francesco Micheli and Paolo Fundarò, with respect to the shares of common stock, par value $0.001 per share (“Common Stock”), of Intercept Pharmaceuticals, Inc. (the “Issuer”). Capitalized terms used in this Amendment without definition have the meanings ascribed to them in the Schedule 13G.

    Items 2(a), 4 and 5 of the Schedule 13G are hereby amended and supplemented to add the following:

    Item 2.
    Ownership:
     
     
    (a)
    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by Genextra, Francesco Micheli, and Paolo Fundarò, who are collectively referred to as the “Reporting Persons.” The Reporting Persons have entered into a Joint Filing Agreement, dated as of July 25, 2019, a copy of which is filed with this Schedule 13G as Exhibit 1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

    Item 4.
    Ownership:
     
    (a)
    Amount beneficially owned:
     
    Genextra beneficially owns 4,000,000 shares of Common Stock.

    Mr. Micheli beneficially owns 4,000,000 shares of Common Stock, consisting of 4,000,000 shares of Common Stock owned by Genextra. Mr. Micheli is an Executive Director and Chairman of the board of Genextra and, in such capacity, Mr. Micheli exercises voting control over the shares of Common Stock owned by Genextra. Mr. Micheli disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.


    Subsequent to the filing of Amendment No. 7 to the Schedule 13G, Mr. Fundarò did not stand for reelection to the board of Genextra and resigned from his position as chief executive officer of Genextra, and although Mr. Fundarò remains employed by Genextra, he is no longer attributed with beneficial ownership of the shares held by Genextra. Mr. Fundarò beneficially owns 55,673 shares of Common Stock, consisting of (a) 28,057 shares of Common Stock owned directly by Mr. Fundarò and (b) an aggregate of 27,616 shares of Common Stock issuable upon the exercise of options that are exercisable or exercisable within sixty days of the date hereof or the vesting of restricted stock units vesting within sixty days of the date hereof.

    The percentage of Common Stock beneficially owned by each Reporting Person as of September 2, 2022 is based on a total of 29,798,040 shares of Common Stock of the Issuer outstanding as of June 30, 2022, as disclosed in the Issuer’s Form 10-Q dated August 3, 2022, filed with the Securities and Exchange Commission on August 3, 2022.

    (b)
    Percent of class:
     
     See Item 11 of each cover page.
     
    (c)
    Number of shares as to which the person has:
     
    (i)
    Sole power to vote or to direct the vote:

    See Item 5 of each cover page.

    (ii)
    Shared power to vote or to direct the vote:
     
    See Item 6 of each cover page.
     
    (iii)
    Sole power to dispose or to direct the disposition of:
     
     See Item 7 of each cover page.
     
    (iv)
    Shared power to dispose or to direct the disposition of:
     
    See Item 8 of each cover page.
     
    Item 5.
    Ownership of Five Percent or Less of a Class:
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
     
    See the information related to Mr. Fundarò in Item 4 above.
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     September 2, 2022
    GENEXTRA S.P.A.
       
     
    By:
    /s/ Francesco Micheli
       
    Name: Francesco Micheli
    Title: Chairman and Chief Executive Officer
       
     September 2, 2022
    /s/ Francesco Micheli
     
    Francesco Micheli
       
     September 2, 2022
    /s/ Paolo Fundarò
     
    Paolo Fundarò

     

    Get the next $ICPT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ICPT

    DatePrice TargetRatingAnalyst
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    5/23/2023Buy → Hold
    Needham
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    5/17/2023Outperform → Mkt Perform
    Raymond James
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    3/3/2022$22.00 → $16.00Sector Perform
    RBC Capital
    3/3/2022$30.00 → $25.00Buy
    Needham
    More analyst ratings

    $ICPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:51:46 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fundaro Paolo returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:47:18 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venezia Rocco returned $278,711 worth of shares to the company (14,669 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:49:33 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intercept Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Intercept Pharma from Sell to Buy and set a new price target of $19.00 from $8.00 previously

      7/13/23 9:10:56 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Intercept Pharma from Hold to Buy and set a new price target of $18.00 from $12.00 previously

      6/29/23 7:24:17 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma downgraded by Needham

      Needham downgraded Intercept Pharma from Buy to Hold

      5/23/23 7:40:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Intercept Pharmaceuticals Inc.

      15-12G - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/20/23 12:09:56 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

      EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/15/23 12:15:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

      EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/15/23 12:15:03 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

      MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. "We are pleased to participate in this year's DDW and share our latest findings, including new data from our Phase 2 trial evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with PBC," said Sangeeta Sawh

      5/9/24 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

      sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supple

      2/29/24 8:30:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

      BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. ("Alfasigma") and Intercept Pharmaceuticals, Inc. ("Intercept") announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma's successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes, Alfasigma acquired all remaining shares of common stock of Intercept through a merger pursuant to Section 251(h) of the General Corporation Law of the St

      11/8/23 9:13:49 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      2/25/22 4:36:46 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      5/27/21 5:23:24 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

      NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer. “Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pleased to welcome her to the team,” said Jerry Durso, President and Chief Executive Officer of Intercept. “She joins us at a pivotal time for the company as we continue to drive our foundational PB

      6/9/21 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

      NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021. Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development and operational execution. She is currently the Chief Operating Officer of Mesoblast Limited. Ms. Rosa-Bjorkeson has led multiple successful product launches, inclu

      2/23/21 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Financials

    Live finance-specific insights

    See more
    • Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

      MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the

      7/26/23 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

      Company to discontinue all NASH-related investment and restructure the Company's operations to strengthen its focus on rare and serious liver diseasesCompany anticipates achieving profitability in 2024 as a result of planned actionsConference call scheduled for Friday, June 23, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company's New Drug Applicat

      6/22/23 5:45:00 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

      12 of 16 voting-eligible advisors vote "no" (with two abstentions) on question, "given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?" 15 of 16 voting-eligible advisors vote to "defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered" PDUFA Target Action Date set for June 22, 2023 Company to host conference call on Monday, May 22, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development

      5/19/23 6:45:00 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      10/10/23 11:07:16 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      7/10/23 10:41:25 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      2/14/23 4:01:07 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care